๐ŸฆŸ Malaria Vaccines

 By Dr. Sk Sabir Rahaman, MBBS, MD (Pharmacology), DFM(Family Medicine), FCFM, CCEBDM, CCLSD

๐Ÿ”น Introduction

  • Malaria is one of the most important parasitic diseases worldwide, mainly caused by Plasmodium falciparum and P. vivax.

  • Despite control measures (vector control, insecticide-treated nets, chemoprophylaxis), malaria remains a leading cause of morbidity and mortality, especially in sub-Saharan Africa and parts of Asia, including India.

  • Historic milestones:

    • RTS,S/AS01 (Mosquirix) → WHO recommendation in 2021 (first malaria vaccine).

    • R21/Matrix-M → WHO prequalification in 2023, with higher efficacy and large-scale Indian production.


๐Ÿ”น Objectives of Malaria Vaccination

  • Reduce malaria incidence, morbidity, and mortality in endemic regions.

  • Complement existing measures (bed nets, insecticides, ACTs, chemoprophylaxis).

  • Prevent severe malaria and deaths in children (the most vulnerable group).

  • Support long-term malaria elimination programs.


๐Ÿ”น Types of Malaria Vaccines

1. RTS,S/AS01 (Mosquirix)

  • WHO approval: 2021 (first malaria vaccine).

  • Type: Recombinant protein vaccine – circumsporozoite protein (CSP) of P. falciparum fused with hepatitis B surface antigen + AS01 adjuvant.

  • Efficacy: ~30–36% against severe malaria.

  • Schedule: 3 primary doses + 1 booster.

  • Limitations:

    • Protection wanes over time.

    • Only partial efficacy.

    • Requires multiple doses.


2. R21/Matrix-M

  • WHO prequalification: 2023.

  • Developed by Oxford University; manufactured by Serum Institute of India (Pune) → ensures large-scale, low-cost supply.

  • Efficacy: ~70–75% (superior to RTS,S).

  • Advantages:

    • Higher efficacy.

    • Lower cost → feasible for mass rollout.

    • Scalable → expected to become mainstay vaccine in endemic regions.


3. Next-Generation Vaccines (in development)

  • Whole sporozoite vaccines (PfSPZ) → irradiated or genetically attenuated sporozoites.

  • Transmission-blocking vaccines → target gametocytes, prevent spread via mosquitoes.

  • mRNA vaccines → experimental, strong immune responses.

  • Viral-vectored vaccines (AdFalciVax, etc.) → under clinical trials.


๐Ÿ”น Indications

  • RTS,S: Children aged 5–17 months in moderate-to-high P. falciparum endemic regions (e.g., sub-Saharan Africa).

  • R21: Same group; broader rollout expected from 2024 onwards.

  • Adults & Travelers: Not yet approved, but studies are ongoing.


๐Ÿ”น Contraindications

  • Severe allergic reaction (anaphylaxis) to vaccine components.

  • Severe acute illness with fever → vaccination deferred.

  • Not indicated for infants <5 months or adults (insufficient data).


๐Ÿ”น Clinical Importance in Public Health

  • First vaccines to reduce malaria-related hospitalizations and deaths.

  • Pilot data (RTS,S in Ghana, Kenya, Malawi):

    • 22% severe malaria hospitalizations.

    • 13% all-cause child mortality.

  • Reduce burden on health systems and improve child survival.

  • Function as a complementary tool alongside vector control and chemoprevention.


๐Ÿ”น Indian Perspective

  • Burden: 2–3 million malaria cases annually. India contributes ~66% of malaria cases in WHO South-East Asia Region.

  • Species trend:

    • P. falciparum → tribal, forested, northeastern states.

    • P. vivax → more common in urban areas.

  • National Framework for Malaria Elimination (NFME 2016–2030) → Goal: malaria-free India by 2030.

  • Role of Vaccines in India:

    • R21/Matrix-M manufactured in Pune → India as global supplier for Africa & Asia.

    • Selective introduction in high-burden states (Odisha, Chhattisgarh, Jharkhand, Northeast).

    • Must be integrated with existing programs (bed nets, IRS, ACTs).


๐Ÿ”น Future Perspectives

  • Combination strategies: Vaccination + chemoprophylaxis.

  • Next-generation platforms: PfSPZ, transmission-blocking, mRNA.

  • Global rollout: R21 likely to dominate due to efficacy and affordability.

  • Ultimate goal: Integrated vaccination + vector control → elimination of malaria.


๐Ÿ”น Conclusion

  • Malaria vaccines mark a landmark achievement in infectious disease control.

  • RTS,S (2021) → first approved vaccine, modest efficacy.

  • R21 (2023, Indian-manufactured) → higher efficacy, affordable, scalable.

  • Though not 100% protective, vaccines significantly reduce severe disease and child mortality.

  • With India’s NFME 2030 goal and role as a vaccine hub, malaria vaccination is poised to become central to elimination strategies both in India and endemic Africa.


Key Take away:
“Malaria vaccines (RTS,S & R21) represent the first successful attempt to immunize against a parasitic disease. They are not curative, but by reducing severe malaria and child mortality, they act as vital adjuncts to existing control measures and are a cornerstone in the global goal of malaria elimination.”  

๐Ÿ“˜ Prepared by Dr. Sk Sabir Rahaman
๐Ÿ“ Specialist Family Physician | Consultant Pharmacologist | Lifestyle & Diabetes Expert

๐ŸŒ Visit My Website for Full Article & other Free PDFs and Resources

Comments

Popular posts from this blog

๐Ÿฅ Insulin Storage: Myths vs. Facts Every Diabetic Should Know

๐Ÿงด TREATMENT OF POISONING – A COMPREHENSIVE OVERVIEW

๐ŸŒฟ Rational Use of Medicines (RUM): A Guide for Safer and Smarter Prescribing